# Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study

> **NCT06335407** · PHASE1 · RECRUITING · sponsor: **Pharmacotherapies for Alcohol and Substance Use Disorders Alliance** · enrollment: 10 (estimated)

## Conditions studied

- Alcohol Use Disorder (AUD)
- Post Traumatic Stress Disorder (PTSD)

## Interventions

- **DRUG:** Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
- **DRUG:** Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg

## Key facts

- **NCT ID:** NCT06335407
- **Lead sponsor:** Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-28
- **Primary completion:** 2026-03-30
- **Final completion:** 2026-05-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-10-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06335407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06335407, "Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06335407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*